These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29519756)

  • 1. Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders.
    Scheffler F; Kilian S; Chiliza B; Asmal L; Phahladira L; du Plessis S; Kidd M; Murray RM; Di Forti M; Seedat S; Emsley R
    Schizophr Res; 2018 Sep; 199():90-95. PubMed ID: 29519756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
    Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
    JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic.
    Chiliza B; Asmal L; Oosthuizen P; van Niekerk E; Erasmus R; Kidd M; Malhotra A; Emsley R
    Eur Psychiatry; 2015 Feb; 30(2):277-83. PubMed ID: 25577186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study.
    Vázquez-Bourgon J; Setién-Suero E; Pilar-Cuéllar F; Romero-Jiménez R; Ortiz-García de la Foz V; Castro E; Crespo-Facorro B
    J Psychopharmacol; 2019 Mar; 33(3):284-294. PubMed ID: 30702972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
    Pappadopulos E; Newcomer JW; Kolluri S
    J Clin Psychiatry; 2012 Jun; 73(6):e742-8. PubMed ID: 22795213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months.
    Luckhoff H; Phahladira L; Scheffler F; Asmal L; du Plessis S; Chiliza B; Kilian S; Emsley R
    Schizophr Res; 2019 Apr; 206():171-176. PubMed ID: 30503765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
    Zhang Y; Dai G
    Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.
    Melkersson KI; Hulting AL; Brismar KE
    J Clin Psychiatry; 2000 Oct; 61(10):742-9. PubMed ID: 11078035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis.
    Basoglu C; Oner O; Gunes C; Semiz UB; Ates AM; Algul A; Ebrinc S; Cetin M; Ozcan O; Ipcioglu O
    Int Clin Psychopharmacol; 2010 May; 25(3):165-71. PubMed ID: 21811193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up.
    Attux C; Quintana MI; Chaves AC
    Braz J Psychiatry; 2007 Dec; 29(4):346-9. PubMed ID: 17992359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations Between Cannabis Use and Cardiometabolic Risk Factors: A Longitudinal Study of Men.
    Meier MH; Pardini D; Beardslee J; Matthews KA
    Psychosom Med; 2019 Apr; 81(3):281-288. PubMed ID: 30589665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients.
    Vázquez-Bourgon J; Ortiz-García de la Foz V; Suarez-Pereira I; Iruzubieta P; Arias-Loste MT; Setién-Suero E; Ayesa-Arriola R; Gómez-Revuelta M; Crespo J; Crespo Facorro B
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Dec; 95():109677. PubMed ID: 31228640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis.
    Gjerde PB; Dieset I; Simonsen C; Hoseth EZ; Iversen T; Lagerberg TV; Lyngstad SH; Mørch RH; Skrede S; Andreassen OA; Melle I; Steen VM
    Schizophr Res; 2018 Jul; 197():253-260. PubMed ID: 29129510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
    Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
    J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis use in people with severe mental illness: The association with physical and mental health--a cohort study. A Pharmacotherapy Monitoring and Outcome Survey study.
    Bruins J; Pijnenborg MG; Bartels-Velthuis AA; Visser E; van den Heuvel ER; Bruggeman R; Jörg F
    J Psychopharmacol; 2016 Apr; 30(4):354-62. PubMed ID: 26883305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial.
    Jensen KG; Correll CU; Rudå D; Klauber DG; Stentebjerg-Olesen M; Fagerlund B; Jepsen JRM; Fink-Jensen A; Pagsberg AK
    J Clin Psychiatry; 2017; 78(8):e1035-e1046. PubMed ID: 28102978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.